146 related articles for article (PubMed ID: 16050908)
1. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
Trumel C; Bourgès-Abella N; Touron C; Lanore D; Geffré A; Diquelou A; Guelfi JF; Braun JP
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):275-9. PubMed ID: 16050908
[TBL] [Abstract][Full Text] [Related]
2. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
Taylor F; Gear R; Hoather T; Dobson J
J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
Vickery KR; Wilson H; Vail DM; Thamm DH
Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
[TBL] [Abstract][Full Text] [Related]
5. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
6. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
[TBL] [Abstract][Full Text] [Related]
7. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
Thamm DH; Mauldin EA; Vail DM
J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
Stanclift RM; Gilson SD
J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
[TBL] [Abstract][Full Text] [Related]
9. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).
Lejeune A; Skorupski K; Frazier S; Vanhaezebrouck I; Rebhun RB; Reilly CM; Rodriguez CO
Vet Comp Oncol; 2015 Sep; 13(3):267-80. PubMed ID: 23721492
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs.
Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK
J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187
[TBL] [Abstract][Full Text] [Related]
11. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases.
Thamm DH; Turek MM; Vail DM
J Vet Med Sci; 2006 Jun; 68(6):581-7. PubMed ID: 16820715
[TBL] [Abstract][Full Text] [Related]
12. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
Krick EL; Billings AP; Shofer FS; Watanabe S; Sorenmo KU
Vet Comp Oncol; 2009 Jun; 7(2):130-8. PubMed ID: 19453367
[TBL] [Abstract][Full Text] [Related]
13. Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997).
McManus PM
J Am Vet Med Assoc; 1999 Aug; 215(3):355-7. PubMed ID: 10434973
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.
Henry CJ; Downing S; Rosenthal RC; Klein MK; Meleo K; Villamil JA; Fineman LS; McCaw DL; Higginbotham ML; McMichael J
Am J Vet Res; 2007 Nov; 68(11):1246-51. PubMed ID: 17975981
[TBL] [Abstract][Full Text] [Related]
15. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy.
Stiborova K; Treggiari E; Amores-Fuster I; Del Busto I; Killick D; Maddox T; Marrington M; Mason SL; Blackwood L
J Small Anim Pract; 2019 Sep; 60(9):534-542. PubMed ID: 31245847
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).
Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE
J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175
[TBL] [Abstract][Full Text] [Related]
17. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
[TBL] [Abstract][Full Text] [Related]
19. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
Cooper M; Tsai X; Bennett P
Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
[TBL] [Abstract][Full Text] [Related]
20. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
